• Endothelial Endoglin Drives Astrocyte Reactivity in Alzheime

  2026-04-24

  This study uncovers how endothelium-derived endoglin (ENG) is transferred via extracellular vesicles to astrocytes, activating inflammatory pathways and contributing to Alzheimer’s disease (AD) pathology. The findings redefine the role of cerebrovascular dysfunction in AD and establish ENG as a mechanistic link and potential therapeutic target.

• Alda 1: ALDH2 Activator for Cardiac Ischemia & Dermatitis Mo

  2026-04-23

  Alda 1 stands out as a powerful ALDH2 activator, enabling breakthrough workflows in cardiac ischemia research and radiation-induced dermatitis mitigation. Explore its mechanistic strengths, protocol optimizations, and evidence-backed troubleshooting strategies for advanced experimental outcomes.

• Cyanine 3 Tyramide: Fluorescent Dye for Biomedical Research

  2026-04-23

  Cyanine 3 Tyramide empowers researchers to detect low-abundance targets in complex tissues with unrivaled sensitivity, especially in immunohistochemistry and in situ hybridization. This APExBIO reagent delivers robust signal amplification, making it a leading choice for advanced neurobiology and molecular labeling workflows.

• Cofilin Activation Drives CCK-Stimulated Pancreatic Secretio

  2026-04-22

  This study reveals that cofilin activation is essential for CCK-stimulated enzyme secretion and growth in pancreatic acinar cells, identifying a convergent signaling node independent of classic kinase pathways. The findings refine understanding of actin dynamics in exocrine pancreas physiology and provide a mechanistic foundation for future inflammation and cancer therapeutics research.

• Targeting AGTR1 in Armored Tumors to Enhance Immunotherapy R

  2026-04-22

  This study systematically identifies angiotensin II receptor 1 (AGTR1) as a key biomarker and therapeutic target in 'armored and cold' tumors, which are typically refractory to immune checkpoint blockade (ICB). By demonstrating that angiotensin II receptor antagonists can remodel the tumor microenvironment and sensitize these tumors to ICB, the work offers a mechanistically informed approach for combination cancer therapies.

• TP53-Dependent Antitumor Action of DHODH Inhibition in NPC

  2026-04-21

  Dong et al. demonstrate that targeting dihydroorotate dehydrogenase (DHODH) potently inhibits nasopharyngeal carcinoma (NPC) cell growth via TP53 activation. This work establishes the significance of nucleic acid metabolism reprogramming in NPC and highlights a promising, TP53-dependent therapeutic strategy.

• AT13387 and Hsp90 Inhibition: Next-Gen Strategies for Transl

  2026-04-21

  This thought-leadership article explores the mechanistic and translational frontiers of AT13387, a potent Hsp90 inhibitor, in cancer biology research. Synthesizing new evidence from apoptosis regulation and DAMP release, it offers strategic guidance for translational researchers seeking to realize the full potential of Hsp90 chaperone inhibition in advanced oncology workflows.

• Cisplatin (CDDP): Mechanistic Benchmarks and Research Utilit

  2026-04-20

  Cisplatin is a platinum-based chemotherapy agent with potent DNA crosslinking and apoptosis-inducing activity. It remains a crucial tool in cancer research for studying tumor cell death, chemoresistance, and oxidative stress responses. This article clarifies cisplatin's molecular mechanisms, benchmarks, and workflow integration with direct, evidence-based claims.

• Lenalidomide (CC-5013): Reliable Solutions for Cancer Resear

  2026-04-20

  This GEO-driven guide explores real laboratory challenges in cell viability and multiple myeloma research, showing how Lenalidomide (CC-5013), SKU A4211, provides reproducible, literature-backed solutions. Scenario-based Q&A address assay optimization, immune modulation, and product reliability—grounded in peer-reviewed data and practical workflows.

• Ionizing Radiation Alters Neuronal Differentiation via PI3K-

  2026-04-19

  This study demonstrates that ionizing radiation (IR) promotes altered neuronal differentiation in C17.2 mouse neural stem-like cells by activating PI3K-STAT3-mGluR1 and PI3K-p53 signaling pathways. The findings advance our understanding of IR-induced neurogenic changes, offering mechanistic insight into potential late effects of brain radiotherapy.

• SM-102 for mRNA Delivery: Protocols, Troubleshooting, and In

  2026-04-18

  SM-102 is a high-purity, ethanol-soluble lipid essential for efficient mRNA vaccine delivery via lipid nanoparticles. This article translates the latest machine learning-driven research and bench protocols into actionable workflows, comparative data, and troubleshooting strategies for researchers optimizing mRNA delivery systems.

• Mitochondrial NAD+ Deficiency Drives Aortic Aneurysm via Col

  2026-04-17

  This study uncovers mitochondrial NAD+ deficiency in vascular smooth muscle as a direct cause of thoracic and abdominal aortic aneurysm, linking impaired proline biosynthesis to defective collagen III turnover. Multiomics analysis and gene knockout models reveal a critical metabolic-structural axis in aortic disease, suggesting new molecular targets for intervention.

• Scalable EPSC-iMSC EV Production: A Platform for Regenerativ

  2026-04-16

  Gong et al. introduce a scalable, standardized platform for generating extracellular vesicles (EVs) from extended pluripotent stem cell (EPSC)-derived mesenchymal stem cells (iMSCs), addressing key hurdles in clinical EV manufacturing. Their bioreactor-based approach delivers high-yield, consistent EVs with therapeutic efficacy in a pulmonary fibrosis model, setting a benchmark for translational regenerative medicine.

• Berbamine Hydrochloride: Applied NF-κB Activity Inhibitor Wo

  2026-04-15

  Berbamine hydrochloride stands out as a research-grade NF-κB activity inhibitor, uniquely combining robust cytotoxicity and signaling modulation in advanced cancer models. Explore optimized workflows, troubleshooting tactics, and insights for overcoming ferroptosis resistance—anchored in the latest mechanistic findings and practical guidance.

• Lenalidomide (CC-5013): Immune Reprogramming and Synergy in

  2026-04-14

  Explore how Lenalidomide (CC-5013) acts as an immune system activation agent and angiogenesis inhibitor in multiple myeloma research. This article uniquely dissects the interplay between epigenetic modulation and immunomodulatory drug efficacy, offering practical guidance and novel insights beyond existing protocols.

414 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page